Trials / Completed
CompletedNCT00913744
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- ThromboGenics · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ocriplasmin | ocriplasmin intravitreal injection (125 µg) |
| DRUG | Sham injection | Sham injection |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2012-12-01
- Completion
- 2013-04-01
- First posted
- 2009-06-04
- Last updated
- 2014-12-17
- Results posted
- 2014-05-05
Locations
27 sites across 6 countries: United States, Belgium, France, Germany, Italy, United Kingdom
Source: ClinicalTrials.gov record NCT00913744. Inclusion in this directory is not an endorsement.